by EpicentRx | Oct 9, 2024 | Company Updates
Let It Be GIFfrom The Beatles GIFs Set to the tune of the Beatles’ song, “Let It Be”, we present words of wisdom from the Third Quarter (Q3). These words of wisdom were not whispered, as in the “Let It Be” song lyrics, but spoken confidently with precise experimental...
by EpicentRx | Oct 4, 2024 | Media
by EpicentRx | Oct 2, 2024 | 2024, Press Releases
San Diego, October 2, 2024 – EpicentRx today announce its lead small molecule, RRx-001 (nibrozetone), is the subject of an oral nanosymposium session in amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) at the 2024 Society for Neuroscience (SfN) during...
by EpicentRx | Sep 30, 2024 | 2024, Press Releases
San Diego, Sept.30, 2024 – EpicentRx, a clinical stage biopharmaceutical company with strong momentum and big plans, will present compelling preclinical data on lead small molecule, RRx-001 (nibrozetone), in Parkinson’s Disease (PD) at the 2024 International Congress...
by EpicentRx | Sep 17, 2024 | 2024, Press Releases
The highly competitive award from the CDMRP Toxic Exposures Research Program will fund the development of EpicentRx’s small molecule, RRx-001 (nibrozetone), as a neuroprotective agent and medical countermeasure against neurotoxic chemical exposures. TORREY PINES, CA,...